drugset / Trial / NCT07110844
Teclistamab-Daratumumab in AL Amyloidosis
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in AL amyloidosis. The study treatment is divided into cycles (C) and each cycle is 28 days (D). Study treatment is expected to last 6 months.
Timeline
- Start
- 2025-11-07
- Primary completion
- 2031-10
- Completion
- 2033-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daratumumab | Monoclonal antibody | — | — |
| Subject | Teclistamab | Monoclonal antibody | — | — |